Gene: KANSL2

54934
C12orf41|NSL2
KAT8 regulatory NSL complex subunit 2
protein-coding
12q13.11
Ensembl:ENSG00000139620 MIM:615488 Vega:OTTHUMG00000170392 UniprotKB:Q9H9L4
NC_000012.12
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.005e-1 (AD)  7.552e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2898086chr12:48675853 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs7315319chr12:48673157 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
UBE2D30.904
DERL10.894
SRSF70.891
DHX150.889
TMED20.882
NOL110.881
OSER10.881
RIOK30.879
RSRC20.876
TIAL10.876

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.654
OR4F29-0.617
HES5-0.237
PTGDR2-0.201
NXNL1-0.187
REM1-0.179
GLI1-0.178
KRTAP19-1-0.175
P2RY14-0.172
TCL1A-0.163

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of KANSL2 mRNA"19114083
D000082AcetaminophenAcetaminophen results in increased expression of KANSL2 mRNA21420995
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of KANSL2 mRNA27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of KANSL2 gene27153756
D001151ArsenicArsenic affects the methylation of KANSL2 gene25304211
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased expression of KANSL2 mRNA"25351596
C006780bisphenol Abisphenol A affects the expression of KANSL2 mRNA21786754
C006780bisphenol Abisphenol A results in increased expression of KANSL2 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of KANSL2 mRNA28628672
D016572CyclosporineCyclosporine results in increased expression of KANSL2 mRNA20106945
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of KANSL2 mRNA28628672
D002945CisplatinCisplatin results in increased expression of KANSL2 mRNA27392435
C000944dicrotophosdicrotophos results in decreased expression of KANSL2 mRNA28302478
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KANSL2 mRNA22079256
D005485FlutamideFlutamide results in increased expression of KANSL2 mRNA24136188
D005557FormaldehydeFormaldehyde results in decreased expression of KANSL2 mRNA20655997
C492448ICG 001ICG 001 results in increased expression of KANSL2 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of KANSL2 mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KANSL2 mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of KANSL2 mRNA28628672
D007657Ketone BodiesKetone Bodies results in increased expression of KANSL2 mRNA16807920
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of KANSL2 mRNA26011545
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of KANSL2 mRNA23649840
C051752nefazodonenefazodone results in increased expression of KANSL2 mRNA24136188
D010416PentachlorophenolPentachlorophenol results in increased expression of KANSL2 mRNA23892564
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KANSL2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of KANSL2 mRNA22079256
D012643SeleniumSelenium results in decreased expression of KANSL2 mRNA19244175
D012822Silicon DioxideSilicon Dioxide results in decreased expression of KANSL2 mRNA25351596
D012834SilverSilver results in increased expression of KANSL2 mRNA27131904
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of KANSL2 mRNA21215274
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KANSL2 mRNA25613284
D013893ThiramThiram results in decreased expression of KANSL2 mRNA20530235
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of KANSL2 mRNA"26179874
D014635Valproic AcidValproic Acid affects the expression of KANSL2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of KANSL2 mRNA23179753|2718838
D001335Vehicle EmissionsVehicle Emissions affects the methylation of KANSL2 gene25560391
C025643vinclozolinvinclozolin results in increased expression of KANSL2 mRNA23034163
D015032ZincZinc deficiency results in decreased expression of KANSL2 mRNA22171008

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI24788516  27705803  
GO:0043995histone acetyltransferase activity (H4-K5 specific)CONTRIBUTES_TOIBA21873635  
GO:0043995histone acetyltransferase activity (H4-K5 specific)contributes_toIDA20018852  
GO:0043996histone acetyltransferase activity (H4-K8 specific)CONTRIBUTES_TOIBA21873635  
GO:0043996histone acetyltransferase activity (H4-K8 specific)contributes_toIDA20018852  
GO:0046972histone acetyltransferase activity (H4-K16 specific)CONTRIBUTES_TOIBA21873635  
GO:0046972histone acetyltransferase activity (H4-K16 specific)contributes_toIDA20018852  
GO ID GO Term Qualifier Evidence PubMed
GO:0043981histone H4-K5 acetylation-IBA21873635  
GO:0043981histone H4-K5 acetylation-IDA20018852  
GO:0043982histone H4-K8 acetylation-IBA21873635  
GO:0043982histone H4-K8 acetylation-IDA20018852  
GO:0043984histone H4-K16 acetylation-IBA21873635  
GO:0043984histone H4-K16 acetylation-IDA20018852  
GO ID GO Term Qualifier Evidence PubMed
GO:0000123histone acetyltransferase complex-IDA20018852  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005829cytosol-IDA-  
GO:0005886plasma membrane-IDA-  
GO:0015629actin cytoskeleton-IDA-  
GO:0044545NSL complex-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-3214847HATs acetylate histonesTAS
R-HSA-3247509Chromatin modifying enzymesTAS
R-HSA-4839726Chromatin organizationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal